Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
2024年6月4日 - 10:00PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced the addition of a new
Universal Plus Panel to its Foresight® Carrier Screen. The panel
includes 39 conditions and screens up to 272 genes associated with
serious inherited conditions.
The conditions added to the Universal Plus panel were named in
the American College of Medical Genetics and Genomics (ACMG)
practice resource for carrier screening. The ACMG calls for
expanded carrier screening to be routinely offered to individuals
who are pregnant or considering becoming pregnant, while also
advising on specific conditions to be tested.
“Building on our efforts to advance equitable and accessible
prenatal care, our latest panel update reflects Myriad’s commitment
to continually growing and innovating to provide genetic insights
that can help guide family planning decisions for every parent,”
said Dale Muzzey, chief scientific officer, Myriad Genetics. “The
genes incorporated into the Universal Plus panel were selected
based on guideline recommendations, associated condition severity,
condition prevalence, clinical actionability of results, and
detection sensitivity.”
Myriad’s expanded carrier screen applies next-generation
sequencing (NGS) and other technologies to find pathogenic variants
underlying heritable genetic diseases, regardless of ancestry. The
Foresight carrier screen offers a detailed report that includes
test results and testing methodology, while also providing free and
on-demand access to genetic counseling resources to help families
and providers understand the report and be informed when
considering next steps.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the addition of a new Universal Plus Panel
to the Foresight Carrier Screen. These “forward-looking statements”
are management’s expectations of future events as of the date
hereof and are subject to known and unknown risks and uncertainties
that could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on February 28, 2024, as well as
any updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 5 2024 まで 6 2024
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 6 2023 まで 6 2024